Cyteir Therapeutics Inc

Description

Cyteir Therapeutics, Inc. engages in the development of novel therapeutics and deoxyribonucleic acid repair and synthetic lethal therapies. It exploits the synthetic lethality of gain-of-function DNA-damaging genes and DNA repair inhibition, resulting in selective death among cells. The company was founded by Kevin Mills and Timothy Romberger in June 2012 and is headquartered in Lexington, MA.